Page 41 Complete Your CE Test Online - Click Here A closer look reveals this example: When a woman is diagnosed with ductal carcinoma in situ (DCIS), she often ends with a mastectomy. But DCIS is considered a Stage 0 cancer (see “Cancer Staging”) – a noninvasive cancer very unlikely to progress to a lethal condition. More than 60,000 women were expected to be diagnosed with it in 2016 alone. Recommended screening tests for cancer by cancer site Colorectal cancer screening There is a range of testing options for colorectal cancer (CRC) screening. (See following for specifics and recommendations for each.) Colonoscopy and sigmoidoscopy also help prevent CRC because they can detect polyps that can be removed before they develop into cancer. CRC risk increases dramatically with age: 90% of all colorectal cancers are diagnosed after age 50, and 93% of CRC deaths occur after that age. Expert groups generally recommend that people who are at average risk for CRC have screening from ages 50 through 75. Screening Can Detect CRC Earlier and Impact Survival The five-year relative survival for localized CRC is 90%, but only 40% of people are diagnosed at this stage, in part because screening is underused. In contrast, five-year relative survival for people with regional CRC is 70%; for those with distant metastases, it is 13%. Nursing consideration: Help patients reduce colorectal cancer mortality risk or even prevent colon cancer by educating them about different colorectal cancer screening options. Help them choose an option that they might actually follow. Most patients will still need screening after cancer treatment, though options will be different if cancer involved the colon or rectum. High-sensitivity fecal Occult blood tests (FOBT) Both polyps and colorectal cancers can bleed, and FOBT checks for tiny amounts of blood in feces that cannot be seen. Blood in stool may also indicate the presence of noncancerous conditions, such as hemorrhoids, but should never be assumed to be the cause when an FOBT is positive. Two types of FOBT are approved by the FDA to screen for colorectal cancer: the older guaiac FOBT, or gFOBT, and the fecal immunochemical (or immunohistochemical) test, or FIT, and also known as iFOBT. With both types of FOBT, stool samples are collected by the patient using a kit, and the samples are returned to the doctor. Note that tests are performed using stool that remains on a gloved finger after a rectal exam are not adequate for screening. Guaiac FOBT uses a chemical to detect heme, a component of hemoglobin. Because the guaiac FOBT can also detect heme in some foods (e.g., red meat), people have to avoid certain foods before having this test. FIT uses antibodies to detect human hemoglobin specifically. Dietary restrictions are typically not required for FIT. Studies have shown that guaiac FOBT, when performed every one to two years in people aged 50 to 80 can reduce the number of deaths from colorectal cancer by 15% to 33%. If FOBT is the only type of colorectal cancer screening test performed, the U.S. Preventive Services Task Force recommends yearly testing. The American Cancer Society notes that it is slightly more effective when a sigmoidoscopy every five years is added to the annual FOBT for people of average risk. The American Cancer Society further notes that patients with an abnormal FOBT will need a colonoscopy. Sigmoidoscopy In this test, the rectum and sigmoid colon are examined using a sigmoidoscope, a flexible lighted tube with a lens for viewing and a tool for removing tissue. This instrument is inserted through the anus into the rectum and sigmoid colon as air or carbon dioxide is pumped into the colon to expand it so the colon lining can be seen more clearly. During sigmoidoscopy, abnormal growths in the rectum and sigmoid colon can be removed for biopsy. The lower colon must be cleared of stool before sigmoidoscopy, but the preparation is less involved than that required for colonoscopy. People are usually not sedated for this test. One randomized controlled clinical trial found that even just one sigmoidoscopy screening between 55 and 64 years of age can substantially reduce colorectal cancer incidence and mortality. Sigmoidoscopy is limited in where it can detect cancer because it can look only at the most distal portion (sigmoid) rather than the whole colon (the more proximal sections, such as the ascending and transverse colon, can harbor malignancy even though no abnormalities show up in the distal portion). This is a concern because according to the National Cancer Institute, about 3% of patients with no distal adenomas have advanced proximal neoplasia. The NCI states that if colonoscopy is performed only in patients with distal polyps, about half the cases of advanced proximal neoplasia will not be detected. The U.S. Preventive Services Task Force recommends sigmoidoscopy every five years along with FOBT every three years for people at average risk who have had negative test results. Sigmoidoscopy cuts CRC mortality, as people over age 50 years who have regular sigmoidoscopy have a 60% to 70% lower risk of death from CRC versus those with no cancer screening. The American Cancer Society notes that sigmoidoscopy every five years is slightly more effective when combined with an annual FOBT in people with average risk. It further notes that patients with an abnormal sigmoidoscopy (polyps, cancer, or other problems) will need a colonoscopy. Standard (or Optical) Colonoscopy In this test, the rectum and entire colon are examined using a colonoscope, a flexible lighted tube with a lens for viewing and a tool for removing tissue. Like the shorter sigmoidoscope, the colonoscope is inserted through the anus into the rectum and the colon as air or carbon dioxide is pumped into the colon to expand it so the colonoscopist can see the colon lining more clearly. Evidence-based practice! Engaging the patient about colonoscopy prep beforehand in the patient’s native language, along with simple written instructions, improves the quality of bowel preparation and supports the sensitivity of colonoscopy, reducing false negatives and the need for repeat colonoscopy because of poor visibility. During colonoscopy, abnormal growths in the colon and the rectum can be removed, including growths in the upper parts of the colon that are not reached by sigmoidoscopy. Polyps and other lesions removed during colonoscopy are typically treated as biopsies and sent to pathology for examination. The kinds of lesions that can be detected include the following: ● ● Nonneoplastic polyps (hyperplastic, juvenile, hamartomatous, inflammatory, and lymphoid polyps), which are not usually considered precursors of cancer. ● ● Neoplastic polyps (adenomatous polyps and adenomas), which are benign lesions that can undergo malignant transformation and become cancer. These are classified into three histologic types with increasing malignant potential: tubular, tubulovillous, and villous. ● ● Cancers. A thorough cleansing of the entire colon is necessary before this test. Most patients receive some form of sedation during the test and will need a chaperone to get home safely. Indirect evidence suggests that colonoscopy reduces deaths from colorectal cancer by about 60% to 70%. Additional studies are currently underway to more directly evaluate how effective colonoscopy is as a primary screening method in reducing death rates. Diagnostic use The colonoscopy is not only used as a basic CRC screening test but also as a follow-up diagnostic test when any other type of CRC screening suggests an abnormality. Also, once a patient has CRC or an adenoma with high-grade dysplasia, her future screenings will no longer be the average-risk person schedule and method. After such a diagnosis, the frequency of CRC screening typically increases, and the standard CRC test usually becomes colonoscopy rather than the less-invasive test options. Less obviously, if a polyp is found and removed during a screening colonoscopy, that colonoscopy may be billed and coded as a diagnostic procedure despite the original intent. This may mean the patient sees